.webp)
The worldwide bacteriophage is expected to grow at a faster rate owing to various reasons, which majorly include the increasing number of research centers due to the increase in inpatient care coupled with the supplement of products. A bacterium is infected by bacteriophages, which are small, virus-like organisms. Bacteriophage enzymes hydrolyze carbohydrate and protein components to destroy bacterial cell walls. They protect the phage's genetic material, ensure that the nucleic acid of the phage is injected into the bacterial cell, and enable the phage to multiply within the bacterium.
Bacteriophages are considered bacteria's natural enemies. Sewage, water, soil, and other environments with bacteria can harbor bacteriophages. As a dietary supplement, Bacteriophages reduce the risk of food-borne infections caused by Escherichia coli, Salmonella, and other gut pathogens.
Business Research Insights forecasts the worldwide market for bacteriophage to hit USD 79 million by 2027, growing at a CAGR of 16.5% during 2022-2027. The increase in antibiotic-resistant production, as well as government funding to support the research and development activities associated with the global market, will drive the growth of this market.
COVID-19 Boosted Market Growth Due to the Increasing R&D Activities for the Formulation of Vaccine
The global supply chain disruption associated with the spread of the COVID-19 pandemic was an adverse effect on the market, thereby causing major market players to shut down temporarily. The sudden lockdown imposed due to the massive spread of the disease also impacted the market. Due to the pandemic, there was a significant disruption in clinical trial executions in the U.S., which affected stakeholders worldwide.
Accordingly, if preventative treatments, vaccinations, or resolutions are not available for diseases like HIV, tuberculosis, and malaria, the pandemic will gradually require a multifaceted strategy. Vaccines have proven highly effective in controlling and limiting the spread of various diseases, such as influenza. The process of finding leads in drug development involves many aspects. Including this, there are many potential bacterial phages that may be useful in controlling the COVID19 pandemic, which had a positive impact on the market.
Business Research Insights Presents the Top 15 Prominent Players in the Bacteriophage Market
1. NPO Microgen
The largest unitary state enterprise producing immunobiological products in Russia is NPO Microgen. Biotechnologies and the introduction of highly effective preparations into healthcare are the two main objectives of NPO Microgen.
2. Proteon Pharmaceuticals
The phage products produced by Proteon Pharmaceuticals take advantage of the natural strengths of bacteriophages. As a pioneer in microbiome modulation, Proteon Pharmaceuticals improves the health of animals and humans. In addition to reducing the need for antibiotics, their products enable more sustainable agriculture, improve food safety and quality, and increase productivity by removing challenges associated with on-farm animal health.
3. Phagelux
Phagelux is a Chinese company that uses bacteriophages to solve bacterial problems in multiple fields, including crop diseases, animal health, food safety, and general sanitary issues. It either outsources the development of its products to third parties or develops them in-house. Third-party phage products are also licensed by Phagelux.
4. Intralytix
Intralytix is a biotechnology company headquartered in the United States that produces and markets bacteriophage-based products for controlling bacterial pathogens in environmental, food processing, and medical settings. The company was the first in the world to receive FDA approval for a food safety bacteriophage product.
5. Micreos
Micreos is an endolysin and phage technology development company based in the Netherlands. It will be the first targeted antibacterial product in the world to replace antibiotics. Micreos develops phage-based products against dangerous bacteria as well as antibacterial solutions for human health and food safety.
6. Eliava BioPreparations
Eliava BioPreparations is a Georgia-based company that manufactures therapeutic and prophylactic bacteriophage preparations.
7. Locus Biosciences
A clinical-stage pharmaceutical company based in Research Triangle Park, North Carolina, Locus Biosciences was founded in 2015. CRISPR-Cas3 gene editing is used in the development of phage therapies, as opposed to CRISPR-Case9, which is delivered by engineered bacteriophages.
8. Pharmex Group, LLC
The most modern manufacturing and research complex in the CIS is Pharmex Group LLC. This complex, unlike most domestic producers, was designed from the very beginning in accordance with EU GMP standards for the pharmaceutical industry.
9. Pherecydes Pharma
Pherecydes Pharma develops lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. This France-based company was founded in 2006.
10. APS Biocontrol Ltd.
In agriculture and food processing, APS Biocontrol Ltd. (APS) develops biocontrol solutions for managing bacterial diseases and other microorganisms. Concerns regarding synthetic chemical use have resulted in a withdrawal program that will greatly affect growers' ability to produce commercial yields and quality, and suppliers' ability to ensure the quality of post-harvest packaged produce.
11. Qingdao Phagepharm Biotech
Qingdao Phagepharm Biotech specializes in industrializing bacteriophages. A major focus of the company is the manufacture and distribution of human and animal health products, food and nutrition ingredients, cosmetics and personal care products, as well as fine chemicals and intermediates.
12. Fixed-Phage Limited
Using targeted phage solutions, Fixed Phage solves bacterial problems. A wide variety of substrates can be covalently attached to bacteriophages using the company's patented technology.
13. Zeptometrix
ZEPTOMetrix is a market leader in designing, developing, and delivering innovative, quality diagnostic solutions for infectious diseases. Since its founding in 1999, ZeptoMetrix has set the industry standard for performance and reliability by providing external quality controls, verification panels, proficiency panels, customized products and OEM services in molecular diagnostics.
14. Phage International, Inc.
Phage International Inc., an American business, deals with several facets of phage therapy, from strain procurement to the management of the most challenging/drug-resistant/chronic infections.
15. Micromir
Micromir is one of the world's leading researchers in phage therapy, both in Russia and internationally. The use of these products is a modern and gentle approach to treating bacterial infections, as well as preventing and treating infectious diseases.
Expanded Antibiotic-Resistant Production to be a Major Driving Factor in the Market
A consistent rise in antibiotic-resistant infections is expected to drive the market rapidly. Apart from it, its wide range of applications is also a major factor in the market's boom. Additionally, government funding to assist bacteriophage market manufacturers in developing a novel approach to reduce the cases of antimicrobial-resistant infections is expected to boost the market. All of these factors have a great influence on the contribution of expanding the market.